The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | CodeBreaK 100: detecting mechanisms of intrinsic resistance by ctDNA
Bob T. Li, MD, MPH, Memorial Sloan Kettering Cancer Center, New York, NY, discusses findings from the Phase I/II CodeBreaK 100 (NCT03600883) of sotorasib in patients with KRAS p.G12C-mutated non–small cell lung cancer (NSCLC) and colorectal cancer (CRC) who have received one prior line of therapy. The objective response rate was 41% and 12% in patients with NSCLC and CRC respectively and the progression-free survival was 6 and 4 months respectively. The two-year overall survival rate was 33% in patients with NSCLC, demonstrating a robust response. Dr Li additionally highlights the use of circulating tumor DNA (ctDNA) to elucidate mechanisms of drug resistance. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
